Failed Head-To-Head Study Clouds Bydureon's Commercial Future
This article was originally published in The Pink Sheet Daily
Executive Summary
With competitive efficacy against successful Victoza now in doubt, Bydureon will need to differentiate itself in other ways.
You may also be interested in...
Lilly Prices Trulicity Near Victoza, But Well Above Tanzeum
Easy-to-use pen with invisible needle to deliver Lilly’s GLP-1 agonist dulaglutide is an asset compared to delivery of other once-weeklies in the class, but the crowded market is still very challenging.
With Bristol/AstraZeneca In Driver’s Seat, GLP-1 Race Takes A Turn
Bristol-Myers and AstraZeneca’s acquisition of Amylin as part of a 50-50 collaboration brings a big new player into the fast-growing GLP-1 class, which is emerging as a key component of treatment in the large, but highly competitive Type 2 diabetes market.
GSK Airs Phase III Data For Weekly GLP-1 Albiglutide, Plans To File By Year-End
GSK/Human Genome Sciences’ once-weekly injectable GLP-1 agonist albiglutide succeeds in a non-inferiority study and should be filed in late 2012. But analysts critique efficacy relative to the competition and some say the diabetes drug will come to the market too late.